Library

Should chronic hepatitis B be treated as early as possible? / Frank Hulstaert in International Journal of Technology Assessment in Health Care, 29(2013)01 ([01/01/2013])  

[article] Should chronic hepatitis B be treated as early as possible? [printed text] / Frank Hulstaert, Author ; Christoph Schwierz, Author ; Frederik Nevens, Author ; Nancy Thiry, Author ; Mohamed Gamil, Author ; Isabelle Colle, Author ; Stefaan Van de Sande , Author ; Yvres Horsmans, Author . - 2013 . - 35-41. Languages : English (eng) in International Journal of Technology Assessment in Health Care > 29(2013)01 [01/01/2013] . - 35-41 Descriptors: Classification W 1 Serials. Periodicals Indexation 2008-11 ; Cost-effectiveness analysis ; Hepatitis B, Chronic ; Journal Article ; Quality of Life ; R127 Abstract: Objectives: We studied the cost-effectiveness of tenofovir and entecavir in e antigen positive (CHBe+) and negative (CHBe-) chronic hepatitis B. Methods: Using a multicenter survey including 544 patients we measured patient quality of life and attributable costs by clinical disease stage. Natural disease progression was studied in 278 patients in a single center. A Markov model was constructed to follow hypothetical cohorts of treated and untreated 40-year-old CHBe+ and CHBe- patients and 50-year-old patients with compensated cirrhosis. Results: We did not find an improvement in quality of life when viral load was reduced under treatment. Transition rates to liver cirrhosis were found to be age-dependent. Assuming equal effectiveness, tenofovir dominates the entecavir strategy because of its lower price in Belgium. The incremental cost-effectiveness ratio (ICER) of tenofovir after 20 years is more favorable for treating Caucasian cirrhotic patients (mean ICER €29,000/quality-adjusted life-year [QALY]) compared with treating non-cirrhotic patients (mean ICER €110,000 and 131,000/QALY for CHB e+ and e-, respectively). Within the non-cirrhotic patients the ICER decreases with increasing cohort starting age from 30 to 50 years. Conclusions: Results of long-term models for tenofovir or entecavir treatment of CHB need to be interpreted with caution as long-term trials with hard end points are lacking. Especially the effect on HCC remains highly uncertain. Based on cost-effectiveness considerations such antiviral treatment should be targeted at patients with cirrhosis or at risk of rapid progression to this disease stage. Link for e-copy: http://dx.doi.org/10.1017/S0266462312000736 Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3737 [article]

Similarities and differences between five European drug reimbursement systems / Margreet Franken in International Journal of Technology Assessment in Health Care, 28(2012)04 ([10/01/2012])  

[article] Similarities and differences between five European drug reimbursement systems [printed text] / Margreet Franken, Author ; Maïté le Polain, Author ; Irina Cleemput , Author ; Marc Koopmanschap, Author . - 2012 . - 3349-357. Languages : English (eng) in International Journal of Technology Assessment in Health Care > 28(2012)04 [10/01/2012] . - 3349-357 Descriptors: Classification W 1 Serials. Periodicals Indexation 2009-19 ; Cost-Benefit Analysis ; Decision Making ; Europe ; Health Policy ; Insurance, Health, Reimbursement ; Journal Article ; Peer Review ; Quality of Health Care ; Quality of Life ; R147 ; statistics and numerical data [Subheading] Abstract: Objectives: The aim of our study is to compare five European drug reimbursement systems, describe similarities and differences, and obtain insight into their strengths and weaknesses and formulate policy recommendations. Methods: We used the analytical Hutton Framework to assess in detail drug reimbursement systems in Austria, Belgium, France, the Netherlands, and Sweden. We investigated policy documents, explored literature, and conducted fifty-seven interviews with relevant stakeholders. Results: All systems aim to balance three main objectives: system sustainability, equity and quality of care. System impact, however, is mainly assessed by drug expenditure. A national reimbursement agency evaluates reimbursement requests on a case-by-case basis. The minister has discretionary power to alter the reimbursement advice in Belgium, France, and the Netherlands. All systems make efforts to increase transparency in the decision-making process but none uses formal hierarchical reimbursement criteria nor applies a cost-effectiveness threshold value. Policies to deal with uncertainty vary: financial risk-sharing by price/volume contracts (France, Belgium) versus coverage with evidence development (Sweden, the Netherlands). Although case-by-case revisions are embedded in some systems for specific groups of drugs, systematic (group) revisions are limited. Conclusions: As shared strengths, all systems have clear objectives reflected in reimbursement criteria and all are prepared to pay for drugs with sufficient added value. However, all systems could improve the transparency of the decision-making process; especially appraisal lacks transparency. Systems could increase the use of (systematic) revisions and could make better use of HTA (among others cost-effectiveness) to obtain value for money and ensure system sustainability. Link for e-copy: http://dx.doi.org/10.1017/S0266462312000530 Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3738 [article]

The European Journal of Health Economics, 7(Suppl.2). The cost of multiple sclerosis in Europe / J._Matthias Graf von der Schulenburg / Berlin - Heidelberg [Germany] : Springer-Verlag (2006)

The European Journal of Health Economics, 7(Suppl.2). The cost of multiple sclerosis in Europe : Costs and quality of life in multiple sclerosis in Europe : method of assessment and analysis [printed text] / J._Matthias Graf von der Schulenburg, Editor . - Berlin - Heidelberg [Germany] : Springer-Verlag, 2006 . - 104 p. Languages : English (eng) Descriptors: Classification WL 360 Multiple sclerosis Indexation Costs and Cost Analysis ; Europe ; Multiple Sclerosis ; Quality of Life Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=501

Hold

Place a hold on this item

Copies(1)

Barcode	Call number	Media type	Location	Section	Status
10273-00637	WL 360/GRA	Journal	KCE	Library (10.124)	Available

The Healthy Life Years (HLY) indicator / JA:EHLEIS (2010)  

The Healthy Life Years (HLY) indicator [electronic document] . - JA:EHLEIS, 2010. Languages : English (eng) French (fre) Descriptors: Indexation Aged ; Databases, Factual ; Europe ; Quality of Life ; statistics and numerical data [Subheading] Classification HN 25 - Statistics. Social indicators. Quality of life Abstract: The proposed new EU structural indicator Healthy Life Years (HLY) is a disability-free life expectancy, one of the most common health expectancies reported. It is based on limitations in daily activities and therefore measures the number of remaining years that a person of a particular age can expect to live without disability. Health expectancies were first developed to address whether or not longer life is being accompanied by an increase in the time lived in good or in bad health. So health expectancies divide life expectancy into life spent in different states of health. In this way they add a dimension of quality to the quantity of life lived. There are as many health expectancies as dimensions of health. Link for e-copy: http://www.healthy-life-years.eu/index.php?c=hly&l=en&s=hly Format of e-copy: Online [Free] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2932

The long-term evolution of quality of life for disease-free breast cancer survivors / Mattias Neyt in Journal of psychosocial oncology, 24(2006)3 ([09/01/2006])

[article] The long-term evolution of quality of life for disease-free breast cancer survivors : a comparative study in Belgium [printed text] / Mattias Neyt , Author ; Johan Albrecht, Author . - 2006 . - 89-123. Languages : English (eng) in Journal of psychosocial oncology > 24(2006)3 [09/01/2006] . - 89-123 Descriptors: Classification WP 870 - Breast - - Neoplasms Indexation Belgium ; Breast Neoplasms ; Journal Article ; Peer Review ; Quality of Life ; Questionnaires ; Survival Rate ; Survivors ; United States Abstract: Aim: Little is known about the long-term evolution of Quality of Life (QoL) for breast cancer treated patients. The study aims to describe this evolution of QoL in a group of Belgian breast cancer survivors. Methods: We gathered information on treatment, general health, activity problems, disease symptoms, pain, emotions, work, social activities, self-care, housekeeping, sexuality, and meaning of life. One hundred seventy-four disease-free survivors in Flanders (Belgium) participated in this study, which were grouped as being disease free less than one year (39), between one and five years (70) and more than five years (65). The data allowed us to analyse QoL for different dimensions over the three survivor groups. Results: The longer the survival time, the more QoL of breast cancer treated patients ameliorated and the less breast cancer had a major impact on QoL. Scores for doing intense activities, being tired, emotional health, social activities, and meaning of life were statistically significantly better in the long-term survivor group. The influence of breast cancer was more persistent for sexual QoL items. Conclusion: It is important for patients to know what they may expect after treatment. This kind of patient-reported information on the evolution of QoL is of great value to healthcare workers. Results may be used to encourage patients who are newly diagnosed with breast cancer or for patients who do not believe in further progress for some QoL aspects. When informing breast cancer patients, a fundamental difference has to be made between the several QoL aspects and time over which improvements may be expected. Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=711 [article]

The Quality of life / Martha Craven Nussbaum / Clarendon Press (1993)

Permalink

Vieillessement osteoarticulaire et politique de santé. Nécessité des évaluations de qualité de vie dans la rationalisation de la prise en charge de l'arthrose / Olivier Ethgen / Liège : Université de Liège.Faculté de Médecine.Département des Sciences de la santé publique.Section... (2003)

Permalink

Voedselconsumptiepeiling / Karin De Ridder / Brussel [Belgium] : WIV=Wetenschappelijk Instituut Volksgezondheid=ISP=Institut Scientifique de Santé Publique (2016)  

Permalink

Which Quality of Life Measures Fit Your Relative Effectiveness Assessment ? / Irina Cleemput in International Journal of Technology Assessment in Health Care, 31(2015)03 ([01/01/2015])  

Permalink